17,261 trials
Glioblastoma · Gliomas
Primary: 12 Month Overall Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concurrent Temozolomide and Radiotherapy Followed by Dose Dense or…
Panic Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 13.30; 13.37; 7.98; 8.32 units on a scale
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Response Rate — 29 percentage of participants
Short-term Insomnia
Primary: Total Sleep Time — 382.9; 339.2; 256.2 minutes
Coronary Artery Disease (CAD)
Primary: Extent of Preservation Of Platelet Inhibitory Effect After Transition From Cangrelor To Prasugrel Or Clopidogrel Compared With Effect Observed With Prasugrel Or…
Cancer of the PROSTATE
Primary: The Percentage of Patients Able to be Sexually Active With or Without the Use of Aids — 88 percentage of patients
Metastatic Sarcoma
Primary: Disease Control Rate — 13; 2; 3 Participants
Multiple Sclerosis
Primary: Cumulative Number of New Gadolinium-enhancing (GdE) T1 Lesions at Week 12 — 4.2; 1.7; 2.2; 2.2 Cumulative number of lesions — p=<0.001
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Colorectal Cancer Metastatic
Primary: Progression Free Survival (PFS) — 6.1; 5.3 Months
Leishmaniasis
Primary: Number of Participants That Discontinued Due to Adverse Experience, by Type of Adverse Experience — 12; 10; 3; 1 Participants
Hypogonadism
Primary: Number of Patients With Adverse Events Receiving Testosterone Enanthate Via QST Auto-injector. — 5; 1; 0; 0 Participants
HCMV
Primary: Number of Participants Who Require Preemptive HCMV Therapy — 24; 23; 9 Count of Participants
Severe Mood Dysregulation
Primary: Clinical Global Impression-Severity-Severe Mood Dysregulation — 4.91; 3.62; 4.30; 4.42 units on a scale — p=.58
Takayasu's Arteritis · Giant Cell Arteritis
Primary: Primary Outcome - Relapse-free Survival (RFS) — 10; 14; 8; 10 Participants — p=0.049